ReadyRx review

What it is

ReadyRx is a US telehealth service organised by category: Metabolic health (compounded semaglutide, compounded tirzepatide, glutathione injection, glutathione nasal spray, metformin), Hormone health (sermorelin injection and sermorelin orally disintegrating tablets), and Energy and Recovery (NAD⁺ injection, NAD⁺ nasal spray, MIC+B12). Brand Ozempic and Zepbound pages exist alongside the compounded line. It states a medical consultation is included in the program so no outside visit is needed, that medication ships in discreet packaging with complimentary shipping, and that it is available across all 50 states.

How it works

Asynchronous, program-priced, and thin on identity. You complete an online consultation, a licensed clinician reviews it, and eligible patients receive medication shipped to the door — with the consultation and shipping both stated as included, which is a real inclusion rather than a hedge. Its quality claim is the notable one: compounded injectables are stated to undergo batch lab testing for potency, sterility, pH and endotoxin. Those four are exactly what an injectable batch should be screened for, and naming them individually is meaningfully better than the vague "third-party tested" language most competitors use. LegitScript certification is displayed with a badge linking to the public checker. What is missing is everyone: the compounding pharmacies are described only as FDA-registered and are never named, and clinicians are described as licensed and board-certified with no names, credentials or NPI numbers published. Multiple molecules are offered in more than one route — sermorelin as injection or orally disintegrating tablet, NAD⁺ and glutathione as injection or nasal spray — which is a genuine convenience, though the alternative routes generally have weaker pharmacokinetic support than the injection.

Pricing transparency

This is the failure. Neither the homepage, the treatments index nor any individual product page contains a dollar figure in the page itself. The number is inserted by a script after load, comes with an asterisk, and is displayed under a "/first mo." suffix — sermorelin as "from $185/mo*" and NAD⁺ as "from $160/mo*" in the underlying default — while the site's own treatment-page footnote states that the price shown applies to quarterly plans paid up front. Three problems compound: a first-month rate is not an ongoing rate, an asterisk with an unstated condition is not a price, and a prepay figure presented as monthly is the pattern this board sees most often and trusts least. We publish no floor for ReadyRx on either board and we would not plan a budget around either figure. Before enrolling, ask for the ongoing monthly charge after month one, whether that requires quarterly prepayment, and what a shipment contains — no dose or vial size is stated anywhere.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. ReadyRx states its compounded injectables are batch-tested for potency, sterility, pH and endotoxin, and that its pharmacies are FDA-registered compounding facilities, though it names none; compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the menu spreads across tiers. Sermorelin is a GHRH analogue stimulating your own pituitary — a real, well-described mechanism with thin long-term human outcome data, and the orally disintegrating tablet route has less pharmacokinetic support than the injection. NAD⁺ is sold here as an injection and as a nasal spray, and neither route has controlled human outcome trials; intranasal NAD⁺ in particular has very little pharmacokinetic characterisation, while the NAD⁺ forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate a benefit. Glutathione, injected or intranasal, has essentially no controlled human outcome data. Metformin is the outlier: an approved drug with decades of trial data for glycaemic control, sold in this context on longevity claims that its own dedicated trial has not yet answered. Individual results vary.

Pros and watch-outs

The evidence behind what ReadyRx prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• NAD⁺ nasal spray: the delivery format with the least direct evidence

  Intranasal NAD⁺ is convenient and heavily marketed — but no controlled human trial shows the spray raises systemic or brain NAD⁺. A straight comparison with the better-studied routes.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How ReadyRx compares

A few alternatives worth a look, depending on what you’re optimizing for.

• PEPepHaūs

  People who will pin the actual NAD⁺ monthly rate down in writing before intake

  See PepHaūs →
• PRPreventiveMD

  NAD⁺ at a published all-in price from a platform that tells you up front whether it can treat you

  See PreventiveMD →
• PAPauseRX

  NAD⁺ buyers who want a named 503A pharmacy and a named prescribing network

  See PauseRX →